Back to top

Image: Bigstock

BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher

Read MoreHide Full Article

BioLineRx Ltd. was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 54.8% in the past one-month time frame.

The move came after the company reported that it has inked a deal with Biokine Therapeutics for increasing its stake in the lead oncology program, BL-8040.

The company has seen two positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for BioLineRx. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

BioLineRx currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.  

Another stock worth considering in the Medical - Drugs industry is BioSpecifics Technologies Corp which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Is BLRX going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


BioLineRx Ltd. (BLRX) - free report >>

Published in